FB23 treatment modulated hepatic genes involved in lipid metabolism and oxidative stress, yet hepatic steatosis remained unchanged. This discordance between molecular markers and tissue pathology suggests unknown regulatory mechanisms that could impact therapeutic efficacy. Gap type: contradiction Source paper: FTO inhibition mitigates high-fat diet-induced metabolic disturbances and cognitive decline in SAMP8 mice. (2025, Molecular medicine (Cambridge, Mass.), PMID:39984825)
Landscape Summary: Why does hepatic steatosis persist despite improved hepatic gene expression profiles? is a 0.73 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why does hepatic steatosis persist despite improved hepatic gene expression profiles? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: